Birmingham Heroes Lecture: Harnessing the immune system
- Leonard Deacon Lecture Theatre, Medical School Building, University of Birmingham
- Alumni, Lectures Talks and Workshops, Medical and Dental Sciences, Research
Immunology is at the forefront of medical research – and the University of Birmingham is among the leaders of this exciting, fast-evolving field. With one of the greatest concentrations of scientists and doctors in the world, the University is also at the cutting edge of immunotherapy – treatment that uses certain parts of a person’s immune system to fight diseases.
In the fifth Birmingham Heroes lecture, Professor Gary Middleton, Professor of Medical Oncology at the University's Institute of Immunology and Immunotherapy, will present the research and work being undertaken by the Cancer Immunology and Immunotherapy Centre (CIIC) at Birmingham, and how they are developing treatments to protect, harness and enhance the immune system's response to cancer. The treatments are designed to stop tumours from blocking or turning off immune responses to the cancer and allow the patient's own body to fight the cancer cells.
Chemotherapy is powerful but indiscriminate: while it attacks cancer cells, it also harms the healthy cells surrounding them. Immunology has been shown to work as well as chemotherapy but with significantly less toxicity, helping to put an end to the terrible suffering that people with cancer currently experience during treatment. Research already completed by the team showed incredibly exciting results in the treatment of solid cancers.
Gary is a Medical Oncologist who specialises in lung cancer and colorectal cancer. He has years of experience in patient treatment, and also in development of novel clinical trials. Appointed to a chair of Medical Oncology at Birmingham in 2013, he is building up a strong clinical research programme in lung and colorectal cancer.
In addition to leading his own clinical research group, Gary is a member of the NCRI Lung Cancer Clinical Studies Group, the advanced lung cancer sub-group, the advanced colorectal sub-group and the pancreatic sub-group. He is a member of the Cancer Research UK Clinical Trials Awards and Advisory Committee (CTAAC). He also holds advisory board membership for a number of drug companies, and is a member of the Cancer Immunology and Immunotherapy Centre’s advisory board.
Please join us for this lecture and drinks reception at the University of Birmingham campus on 17 October from 6.30pm to 8.30pm. Following the lecture, you will have a chance to meet with Gary and network with alumni and friends of the University over drinks. Please register using the link above.